ARTICLE | Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
January 6, 2025 10:48 PM UTC
It was another year of best-in-class drug approvals by FDA with established mechanisms and markets dominating the new product landscape.
An analysis of therapeutics approved by FDA in 2024 finds a drop in advanced modalities, with cell and gene therapies failing to achieve the breakout year projected. ...